(IDNA) iShares Genomics Immunology - Ratings and Ratios
Pharmaceuticals, Diagnostics, Gene Editing, Vaccines
Dividends
| Dividend Yield | 1.00% |
| Yield on Cost 5y | 0.56% |
| Yield CAGR 5y | 16.63% |
| Payout Consistency | 82.8% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 23.4% |
| Value at Risk 5%th | 39.2% |
| Relative Tail Risk | 1.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.46 |
| Alpha | -0.04 |
| CAGR/Max DD | 0.06 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.454 |
| Beta | 0.822 |
| Beta Downside | 0.710 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.56% |
| Mean DD | 16.07% |
| Median DD | 15.78% |
Description: IDNA iShares Genomics Immunology November 30, 2025
The iShares Genomics Immunology and Healthcare ETF (NYSE ARCA: IDNA) commits at least 80% of its capital to the securities that make up its underlying index-or to assets that closely mimic those securities-and may allocate the remaining portion to futures, options, swaps, cash, or cash equivalents.
Key quantitative points (as of the latest filing): the fund carries an expense ratio of 0.45%, holds roughly $1.2 billion in assets under management, and its top holdings include CRISPR Therapeutics, Illumina, and Moderna, together representing about 12% of the portfolio. The genomics and immunology sectors are projected to grow at a CAGR of 12-15% through 2030, driven by increasing demand for personalized medicine, expanding biotech R&D budgets, and favorable regulatory pathways for gene-editing therapies.
For a deeper, data-rich analysis of IDNA’s risk-adjusted performance and sector exposure, you might explore ValueRay’s research tools to supplement your due-diligence.
What is the price of IDNA shares?
Over the past week, the price has changed by -0.97%, over one month by +1.49%, over three months by +17.52% and over the past year by +14.42%.
Is IDNA a buy, sell or hold?
What are the forecasts/targets for the IDNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29 | 9.4% |
IDNA Fundamental Data Overview December 15, 2025
Beta = 1.42
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 132.0m USD (132.0m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 132.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 132.0m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.05% (E(132.0m)/V(132.0m) * Re(9.05%) + (debt-free company))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IDNA ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle